GB201015765D0 - Use of myeloid cell biomarkers for the diagnosis of cancer - Google Patents

Use of myeloid cell biomarkers for the diagnosis of cancer

Info

Publication number
GB201015765D0
GB201015765D0 GBGB1015765.9A GB201015765A GB201015765D0 GB 201015765 D0 GB201015765 D0 GB 201015765D0 GB 201015765 A GB201015765 A GB 201015765A GB 201015765 D0 GB201015765 D0 GB 201015765D0
Authority
GB
United Kingdom
Prior art keywords
biomarkers
cancer
diagnosis
rcc
crc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1015765.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immatics Biotechnologies GmbH
Original Assignee
Immatics Biotechnologies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies GmbH filed Critical Immatics Biotechnologies GmbH
Priority to GBGB1015765.9A priority Critical patent/GB201015765D0/en
Publication of GB201015765D0 publication Critical patent/GB201015765D0/en
Priority to SG10201510470WA priority patent/SG10201510470WA/en
Priority to EA201390413A priority patent/EA201390413A1/ru
Priority to US13/239,011 priority patent/US9671404B2/en
Priority to JP2013528723A priority patent/JP5970459B2/ja
Priority to KR1020137010009A priority patent/KR20130137635A/ko
Priority to CA2811070A priority patent/CA2811070A1/en
Priority to SG2013018973A priority patent/SG188543A1/en
Priority to CN201180045200.3A priority patent/CN103180739B/zh
Priority to PCT/EP2011/066397 priority patent/WO2012038463A2/en
Priority to EP11758209.8A priority patent/EP2619585B1/en
Ceased legal-status Critical Current

Links

Classifications

    • G01N33/575—
    • G01N33/57535—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5751—
    • G01N33/57525—
    • G01N33/5753—

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
GBGB1015765.9A 2010-09-21 2010-09-21 Use of myeloid cell biomarkers for the diagnosis of cancer Ceased GB201015765D0 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
GBGB1015765.9A GB201015765D0 (en) 2010-09-21 2010-09-21 Use of myeloid cell biomarkers for the diagnosis of cancer
EP11758209.8A EP2619585B1 (en) 2010-09-21 2011-09-21 Use of myeloid cell biomarkers for the diagnosis of cancer
JP2013528723A JP5970459B2 (ja) 2010-09-21 2011-09-21 がん診断用バイオマーカーに対する骨髄細胞の使用
EA201390413A EA201390413A1 (ru) 2010-09-21 2011-09-21 Применение миелоидных клеток в качестве биомаркеров в диагностике рака
US13/239,011 US9671404B2 (en) 2010-09-21 2011-09-21 Use of myeloid cell biomarkers for the diagnosis of cancer
SG10201510470WA SG10201510470WA (en) 2010-09-21 2011-09-21 Use of myeloid cell biomarkers for the diagnosis of cancer
KR1020137010009A KR20130137635A (ko) 2010-09-21 2011-09-21 암의 진단을 위한 골수 세포 생체지표의 용도
CA2811070A CA2811070A1 (en) 2010-09-21 2011-09-21 Use of myeloid cell biomarkers for the diagnosis of cancer
SG2013018973A SG188543A1 (en) 2010-09-21 2011-09-21 Use of myeloid cell biomarkers for the diagnosis of cancer
CN201180045200.3A CN103180739B (zh) 2010-09-21 2011-09-21 利用骨髓细胞生物标记诊断癌症
PCT/EP2011/066397 WO2012038463A2 (en) 2010-09-21 2011-09-21 Use of myeloid cell biomarkers for the diagnosis of cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1015765.9A GB201015765D0 (en) 2010-09-21 2010-09-21 Use of myeloid cell biomarkers for the diagnosis of cancer

Publications (1)

Publication Number Publication Date
GB201015765D0 true GB201015765D0 (en) 2010-10-27

Family

ID=43065538

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1015765.9A Ceased GB201015765D0 (en) 2010-09-21 2010-09-21 Use of myeloid cell biomarkers for the diagnosis of cancer

Country Status (10)

Country Link
US (1) US9671404B2 (enExample)
EP (1) EP2619585B1 (enExample)
JP (1) JP5970459B2 (enExample)
KR (1) KR20130137635A (enExample)
CN (1) CN103180739B (enExample)
CA (1) CA2811070A1 (enExample)
EA (1) EA201390413A1 (enExample)
GB (1) GB201015765D0 (enExample)
SG (2) SG188543A1 (enExample)
WO (1) WO2012038463A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
EP3682896A1 (en) * 2011-04-28 2020-07-22 University of Southern California Human myeloid derived suppressor cell cancer markers
WO2013169913A1 (en) * 2012-05-08 2013-11-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Predictors of patient response to interferon-a therapy
US20160030558A1 (en) * 2013-03-13 2016-02-04 Health Research, Inc. Enhancement of vaccines
CN103743907B (zh) * 2013-07-24 2015-04-15 北京大学人民医院 测定造血干细胞移植后患者骨髓微循环环境评测的试剂盒、系统及方法
WO2015048748A1 (en) * 2013-09-30 2015-04-02 Board Of Regents, The University Of Texas System Myeloid-derived suppressor cell-specific peptides for diagnostic and therapeutic use
CN103626846B (zh) * 2013-11-08 2016-06-01 上海交通大学 与MDSCs特异性结合的配体多肽及药物输送系统
EP3012271A1 (en) * 2014-10-24 2016-04-27 Effimune Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases
WO2016210241A1 (en) * 2015-06-26 2016-12-29 Beth Israel Deaconess Medical Center, Inc. Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
MX2018002640A (es) * 2015-09-02 2018-06-20 Syndax Pharmaceuticals Inc Seleccion de pacientes para la terapia de combinacion.
KR102883915B1 (ko) 2015-12-16 2025-11-18 시애틀 프로젝트 코포레이션 신생항원 동정, 제조, 및 용도
GB201604490D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides combination of peptides for use in immunotherapy against cancers
EP4438626A3 (en) 2016-04-14 2024-12-04 OSE Immunotherapeutics New anti-sirpa antibodies and their therapeutic applications
NZ754222A (en) 2016-12-08 2022-02-25 Immatics Biotechnologies Gmbh T cell receptors with improved pairing
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
CN107102127B (zh) * 2017-04-07 2019-08-06 东北师范大学 一种人体外周血中单核样髓源抑制细胞的检测方法
AU2018269039B2 (en) 2017-05-19 2025-05-15 Syndax Pharmaceuticals, Inc. Combination therapies
WO2018221820A1 (ko) * 2017-06-02 2018-12-06 이종균 대장 직장암 환자와 정상인의 말초혈액 내 면역세포의 분포 차이를 이용하여 면역력을 평가하고 암 발병 유무에 대한 정보를 제공하는 방법 및 이를 이용한 진단키트
JP7227237B2 (ja) 2017-10-10 2023-02-21 グリットストーン バイオ インコーポレイテッド ホットスポットを利用した新生抗原の特定
US11713356B2 (en) 2017-10-13 2023-08-01 Ose Immunotherapeutics Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
KR102216725B1 (ko) * 2017-12-29 2021-02-17 연세대학교 산학협력단 면역 항암 요법에 대한 치료 반응 예측 방법
CA3091468A1 (en) 2018-03-13 2019-09-19 Ose Immunotherapeutics Use of anti-human sirpa v1 antibodies and method for producing anti-sirpa v1 antibodies
WO2019217484A1 (en) 2018-05-07 2019-11-14 Syndax Pharmaceuticals, Inc. Selection of patients for combination therapy
CN110501483B (zh) * 2019-07-25 2020-12-29 同济大学 一种中草药活性的检测方法
TR202003833A1 (tr) 2020-03-12 2021-09-21 Hacettepe Ueniversitesi Rektoerluek Mi̇yeloi̇d kökenli̇ baskilayici hücrelere özgü bi̇yobeli̇rteç paneli̇
EP4347653A1 (en) 2021-06-04 2024-04-10 Boehringer Ingelheim International GmbH Anti-sirp-alpha antibodies
CN117054649A (zh) * 2023-08-04 2023-11-14 广州中医药大学第一附属医院 一种慢性萎缩性胃炎向胃癌转化标志物及其应用
CN117030580B (zh) * 2023-09-15 2024-07-16 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） LDNs在坏死性小肠结肠炎诊断中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US20040136973A1 (en) * 2002-11-07 2004-07-15 Eliezer Huberman Human stem cell materials and methods
US8329408B2 (en) * 2005-10-31 2012-12-11 Bayer Healthcare Llc Methods for prognosis and monitoring cancer therapy
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
GB0820698D0 (en) * 2008-11-12 2008-12-17 Ludwig Inst Cancer Res Uses of immunomodulators

Also Published As

Publication number Publication date
CN103180739B (zh) 2016-08-03
CN103180739A (zh) 2013-06-26
SG188543A1 (en) 2013-04-30
JP5970459B2 (ja) 2016-08-17
JP2013539857A (ja) 2013-10-28
US9671404B2 (en) 2017-06-06
WO2012038463A3 (en) 2012-07-26
EP2619585A2 (en) 2013-07-31
KR20130137635A (ko) 2013-12-17
SG10201510470WA (en) 2016-01-28
WO2012038463A2 (en) 2012-03-29
EA201390413A1 (ru) 2013-07-30
US20120070461A1 (en) 2012-03-22
CA2811070A1 (en) 2012-03-29
EP2619585B1 (en) 2017-03-01

Similar Documents

Publication Publication Date Title
GB201015765D0 (en) Use of myeloid cell biomarkers for the diagnosis of cancer
IL254062B (en) Kits containing ptk7 antibody and their use in the treatment, detection, diagnosis or monitoring of cancer
WO2009037572A3 (en) Biomarker combinations for colorectal cancer
MX2019004193A (es) Combinacion de anticuerpos anti-kir y anticuerpos anti-pd-1 para tratar cancer.
IL219405A0 (en) Diagnostic methods for determining prognosis of non-small cell lung cancer
IN2014DN07019A (enExample)
TN2013000358A1 (en) Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects
MX2020009704A (es) Metodo para usar expresion genica para determinar la probabilidad de un desenlace clinico de cancer renal.
WO2012106718A3 (en) Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
MY176706A (en) Biomarkers and methods of treating pd-1 and pd-l1 related conditions
HK1199100A1 (en) Methods and compositions for the treatment and diagnosis of colorectal cancer
HK1213924A1 (zh) 用於治療癌症的抗kir和抗ctla-4抗體組合
PH12012500711B1 (en) Monoclonal antibodies to progastrin and their uses
MX2013000917A (es) Metodos para detectar las enfermedades o condiciones usando celulas fagociticas.
WO2009094647A3 (en) P53 biomarkers
EP4497824A3 (en) Methods and materials for assessing loss of heterozygosity
WO2011139721A8 (en) Cancer biomarkers and methods of use thereof
EA201390744A1 (ru) Антикластериновые антитела и антигенсвязывающие фрагменты и их использование для уменьшения объема новообразований
WO2012071096A3 (en) Arid1a and ppp2r1a mutations in cancer
NZ629555A (en) Monocyte biomarkers for cancer detection
IL245766A0 (en) Different levels in blood cell samples of emt markers for the diagnosis of cancer, in particular colon cancer (crc) and pancreatic cancer (pc)
WO2014078468A3 (en) Biomarkers for predicting clinical response of cancer patients to treatment with immunotherapeutic agent
EA201390694A1 (ru) Способы лечения рака
WO2010009171A3 (en) Src activation for determining cancer prognosis and as a target for cancer therapy
IL219367A0 (en) Diagnostic methods for determining prognosis of non-small cell lung cancer

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)